Press Release FeedGet the RSS feed
Menu

Business Wire

ŌURA Announces Launch of Initial Public Offering

Jefferies Financial Group

SAN FRANCISCO, September 21, 2026--ŌURA, a leading health intelligence platform and maker of the world's smallest smart ring, today announced that it has launched its initial public offering of 50,000,000 shares of its common stock. The offering consists of 13,500,000 shares offered by Oura and 36,500,000 shares offered by certain of Oura's existing stockholders. In addition, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 7,500,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Oura will not receive any proceeds from the sale of its common stock by the selling stockholders. The initial public offering price is expected to be between $40.00 and $44.00 per share.

Oura has applied to list its common stock on the Nasdaq Global Select Market under the ticker symbol "OURA."

Goldman Sachs & Co. LLC, Morgan Stanley, J.P. Morgan, Allen & Company LLC, and Jefferies are acting as joint lead book-running managers for the proposed offering. BofA Securities, Barclays, and Wells Fargo Securities are acting as joint book-running managers. Citizens Capital Markets, KeyBanc Capital Markets, and Guggenheim Securities are acting as book-running managers. Canaccord Genuity, Needham & Company, Raymond James, Rothschild & Co, Truist Securities, and William Blair are acting as additional book-running managers. Robinhood is acting as a co-manager.

The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus, when available, may be obtained from:

  • Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at [email protected];

  • Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, Second Floor, New York, NY 10014, or by email at [email protected];

  • J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected];

  • Allen & Company LLC, Attention: Prospectus Department, 711 Fifth Avenue, 9th floor, New York, NY 10022, by telephone at (212) 339-2220, or by email at [email protected]; or

  • Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected].

  1. Biotech & pharmaCity Therapeutics Announces Pricing of Upsized Initial Public OfferingCompanies: Jefferies Financial GroupCity Therapeutics Announces Pricing of Upsized Initial Public Offering
  2. FinanceCoVolt Power, Inc.CoVolt Power Announces Public Filing of Registration Statement for Proposed Initial Public OfferingCompanies: Jefferies Financial GroupHOUSTON, August 21, 2026--CoVolt Power, Inc. ("CoVolt Power" or the "Company"), today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of shares of its Class A common stock.
  3. FinanceAres Acquisition Corporation IIIAres Acquisition Corporation III Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing August 20, 2026Companies: Jefferies Financial GroupNEW YORK, August 20, 2026--Ares Acquisition Corporation III (NYSE: AAC.U) (the "Company"), a special purpose acquisition company formed for the purpose of entering into a combination with one or more businesses, today announced that, commencing August 20, 2026, holders of the 39,500,000 units sold in the Company’s initial public offering (the "Units"), completed on July 1, 2026, may elect to separately trade the Class A ordinary shares and warrants included in the Units. Those Units not separate
  4. FinanceSilence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSsCompanies: Jefferies Financial GroupMorgan StanleyLONDON, August 14, 2026--Silence Therapeutics plc, (Nasdaq: SLN), ("Silence" or the "Company"), a global clinical-stage biotechnology company developing novel short interfering RNA ("siRNA") therapies, today announced the closing of its previously announced underwritten public offering of 14,907,407 American Depositary Shares ("ADSs"), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States at a public offering price of $13.50 per ADS, which incl